Trial Profile
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Acronyms LIBERTY ASTHMA TRAVERSE; TRAVERSE
- Sponsors Sanofi
- 25 Nov 2023 Results of post-hoc analysis from NCT02134028 and NCT02414854; investigating long-term dupilumab efficacy in reducing exacerbations across yearly seasons in patients with type 2 inflammatory asthma with and without clinical evidence of allergic asthma, published in the Annals of Allergy, Asthma and Immunology
- 01 Oct 2023 Results of post-hoc analysis of 2 studies (LIBERTY ASTHMA QUEST trial (NCT02414854) and TRAVERSE open-label extension (NCT02134028) ) assessing dupilumab efficacy, published in the Clinical and Experimental Allergy.
- 13 Sep 2023 Results evaluating long term annualized severe exacerbation rate, presented at the 33rd Annual Congress of the European Respiratory Society